The real question for business leaders is not whether AI is overhyped, but how to harness its capabilities to drive ...

European stocks closed in negative territory on Wednesday as regional market jitters grew over U.S. President Donald Trump's ...

Editorial: Over the holiday period, the Guardian leader column is looking ahead at the themes of 2026. Today we examine how the White House’s war on vaccines has left the future of a key technology un ...

Explore how nanotechnology acts as the 'Convergence Engine' for AI materials discovery, CRISPR gene therapy delivery, and ...

An update from Moderna ( ($MRNA) ) is now available. In a January 5, 2026 letter to shareholders, Moderna reviewed a challenging 2025 operating ...

Apple’s tvOS is the best smart TV operating system, while Hisense's VIDAA is the worst. Here’s how the other TV operating systems compare to these two.

Moderna has rallied ~23%, but I maintain a 'Sell' and 'market underperform' rating due to deteriorating fundamentals. MRNA’s recent rally is driven by improved liquidity, cost discipline, and a $1.5 ...

Operating rooms are critical to surgical care and hospital revenue, but inefficiencies in the OR are a challenge at nearly ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the afternoon session after the broader biotech sector experienced a strong rebound, lifting shares of companies within the industry.

Dec 18 (Reuters) - Moderna (MRNA.O), opens new tab will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental bird flu vaccine, the U.S.

The European Medicines Agency’s Committee for Medicinal Products for Human Use previously issued a positive opinion recommending marketing authorization of Moderna’s new COVID-19 vaccine, mNEXSPIKE ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this week, including a cancer drug from ImmunityBio (IBRX) and Moderna's (MRNA) ...